England has become the first European country to approve teplizumab, an immunotherapy that delays the onset of type 1 diabetes, through a formal health technology appraisal. The National Institute for Health and Care Excellence recommended the drug for NHS use in final draft guidance issued June 23, 2026, offering people in the early stage of the condition an average of nearly three years before they develop symptoms and need insulin.
Key Takeaways
- The National Institute for Health and Care Excellence recommended teplizumab for NHS use in final draft guidance on June 23, 2026.
- England is the first European country to back the immunotherapy through a health technology appraisal.
- Teplizumab delays the onset of symptomatic type 1 diabetes by an average of nearly three years.
- The treatment is for children aged eight and older and adults in the pre-symptomatic stage 2 of the disease.
- Around 1,100 people could be eligible in the first year across England and Wales.
What Teplizumab Does
Teplizumab, sold as Tzield and made by Sanofi, is the first immunotherapy that targets the underlying cause of type 1 diabetes rather than managing its consequences. Type 1 diabetes develops when the immune system attacks the insulin-producing beta cells in the pancreas. Most people are diagnosed only once they reach the symptomatic phase, known as stage 3, when blood sugar rises and lifelong insulin treatment becomes necessary. Before that, the disease passes through two earlier, asymptomatic stages in which the immune system is already producing autoantibodies that damage the pancreas.
The drug works by binding to a protein on the surface of the T-cells that drive that attack, slowing the immune process. It is given intravenously as a single course, administered once a day for 14 consecutive days. In a landmark clinical trial reviewed by an independent NICE committee, teplizumab delayed progression to symptomatic type 1 diabetes. Trial results showed the time to onset of stage 3 was 59.6 months in patients who received teplizumab, compared with 27.1 months in the placebo group, a difference of roughly two to three years.
Who Is Eligible
The National Institute for Health and Care Excellence recommended teplizumab for adults and children aged eight and older who have stage 2 type 1 diabetes, the pre-symptomatic phase in which the disease can be detected before symptoms appear. NICE estimates that around 1,100 people could be eligible across England and Wales in the first year, a figure that includes patients already identified through current screening trials who have been waiting for a treatment option. From the third year onward, the eligible population is expected to settle at approximately 820 patients annually.
Detecting the disease early is central to the treatment’s benefit, since teplizumab can only help patients identified before symptoms begin. Diabetes UK, which welcomed the decision, has called for national services to detect and treat type 1 diabetes early, with fair and equitable access for everyone. That early-detection challenge means the therapy’s real-world reach will depend on expanding screening, a point clinicians have emphasized alongside the approval.
Why the Decision Matters
The recommendation was framed by researchers and clinicians as a turning point in a field that has relied on insulin for a century. Dr. Elizabeth Robertson, director of research and clinical at Diabetes UK, said the approval marks the start of a new age of type 1 diabetes treatment, describing it as the first time in 100 years that care has moved beyond insulin toward a medicine that targets the root cause of the condition.
Helen Knight, director of medicines evaluation at NICE, called it a genuinely exciting recommendation, saying it gives people diagnosed at an early stage precious extra time before they face the full demands of managing the disease. She noted that the decision balanced clinical benefit against value for taxpayers, consistent with the health body’s appraisal process.
The extra window carries practical weight for patients and families. It offers time to prepare for a condition that requires constant monitoring of blood sugar, careful management of diet and activity, and lifelong insulin therapy. For children in particular, delaying that burden by two to three years can mean additional time in school and daily life before the demands of active management begin.
Access and Next Steps
Teplizumab will be available to NHS patients in England within 90 days of the publication of NICE’s final guidance, and patients in Wales will be able to access it within 60 days. To deliver the treatment in practice, the NHS will need to build new testing and treatment pathways, since patients must be identified at stage 2 for the therapy to work. Work to develop that infrastructure is already under way, supported by screening research such as the Diabetes UK-backed ELSA study, which has explored what childhood screening for type 1 diabetes could look like in the real world.
England’s approval positions the country at the front of a global shift toward early intervention in type 1 diabetes, turning a long-studied immunotherapy into a treatment that can give patients years of life before insulin dependence begins.
This article is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare professional regarding diagnosis and treatment.
Frequently Asked Questions
What is teplizumab? Teplizumab, sold as Tzield and made by Sanofi, is the first immunotherapy that targets the root cause of type 1 diabetes by slowing the immune attack on insulin-producing cells.
How long does it delay type 1 diabetes? Clinical trial data showed teplizumab delays the onset of symptomatic type 1 diabetes by an average of nearly three years, with progression to stage 3 reaching 59.6 months versus 27.1 months on placebo.
Who can receive the treatment? NICE recommended it for children aged eight and older and adults in the pre-symptomatic stage 2 of type 1 diabetes.
How is teplizumab given? It is administered intravenously as a one-time course, once a day for 14 consecutive days.
When will NHS patients be able to access it? The treatment will be available within 90 days of final guidance in England and within 60 days in Wales.
Why is early detection important? Teplizumab only helps patients identified at stage 2, before symptoms appear, so expanding screening is key to reaching eligible people.
